Tag: Zilver PTX
Real-world registry shows sustained efficacy for Eluvia DES in the SFA
This advertorial is sponsored by Boston Scientific.
During a satellite symposium session dedicated to real cases and trial outcomes which was held at the Cardiovascular...
Paclitaxel puzzles: Final word on the controversy
Following his statement titled ‘Paclitaxel meta-analyses in the lower limbs: Missing the trees for the forest’ published in the June issue of The Journal...
Calls in Germany for reimbursement as analysis shows drug-eluting technology is...
Stefan Müller-Hülsbeck (Ev Luth Diakonissenanstalt zu Flensburg, Flensburg, Germany) presented attendees of the online meeting of the Cardiovascular and Interventional Radiological Society of Europe...
New prediction model for target lesion revascularisation grants “new level of...
“Please feel free to utilise this in your practice,” Michael Dake (University of Arizona Health Sciences, Tucson, USA) urged on the first day of...
VIVA 2019: Zilver PTX shows benefits across different patient groups
At this year’s Vascular Interventional Advances (VIVA) conference (4–7 November, Las Vegas, USA), Michael D Dake presented data on Zilver PTX that supports the...
New Cook Medical paclitaxel data confirm safety of Zilver PTX
New data on the use of Zilver PTX, Cook Medical’s paclitaxel-coated stent for peripheral arterial disease (PAD), confirms the safety of the device. These...
Cook leads the way to data transparency with release of long-term...
There were calls for greater transparency and sharing of the available randomised controlled trial data of paclitaxel-coated devices at the CX 2019 Highlight Session, Paclitaxel:...
Latest data from Philips reinforces the safety profile of Stellarex low-dose...
A new pooled analysis of patient-level data from Philips demonstrates the “strong safety profile” of the its Stellarex drug-coated balloon (DCB) in above-the-knee studies,...
Data presented at LINC confirm the safety and effectiveness of Zilver...
Findings presented at the Leipzig Interventional Course (LINC; 22–25 January 2019, Leipzig, Germany) contradict the results of a meta-analysis published in the Journal of...
New Zilver PTX global data finds 76% freedom from TLR at...
Results from an aggregated data analysis of the use of the Zilver PTX drug-eluting peripheral stent (DES; Cook Medical) in challenging patient populations concluded...
Five-year evaluation of Zilver PTX stent in a real-world population continues...
Five-year results from a Japanese post-market surveillance study aimed at evaluating the Zilver PTX drug-eluting stent (DES) in a real-world population show consistently positive...
Cook Medical receives FDA approval for first 5mm diameter SFA drug-eluting...
Cook Medical have announced that a new 5mm diameter version of Zilver PTX was approved by the US Food and Drug Administration (FDA). It...
Eluvia outperforms Zilver PTX in IMPERIAL 12-month results
The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...
Cook Medical introduces a new length of Zilver PTX
Cook Medical has introduced the 140mm-length Zilver PTX drug-eluting peripheral stent in both 6 and 7mm diameters in the USA. The longer length comes...
